KCNH1-Associated Disorder: Comprehensive Disease-Characteristics Report

Executive summary

KCNH1-associated disorder is an autosomal-dominant neurodevelopmental potassium-channelopathy spectrum caused principally by heterozygous activating missense variants in KCNH1, which encodes the voltage-gated potassium channel Kv10.1/Eag1. The spectrum includes Temple–Baraitser syndrome (TMBTS), KCNH1-related Zimmermann–Laband syndrome type 1 (ZLS1), syndromic developmental delay with hypotonia and epilepsy, developmental and epileptic encephalopathy (DEE), and—based on newer evidence—milder isolated febrile seizures or epilepsy. Boundaries between TMBTS and ZLS1 are clinically and molecularly porous; it is often more accurate to represent them as overlapping manifestations of one KCNH1-related spectrum. (tian2023phenotypicexpansionof pages 1-2, wrede2021novelkcnh1mutations pages 1-2, gripp2021syndromicdisorderscaused pages 1-2)

The best recent aggregate analysis included 51 affected individuals and 30 variants: 42/51 (82%) had epilepsy or seizures, 38/51 carried de novo variants, and 49/51 (96%) had missense variants. Inherited, mosaic, or brain-somatic variants generally produced later-onset or more restricted epilepsy, whereas recurrent de novo variants in voltage-sensor S4 and pore-associated S6 regions were enriched in severe early-onset epilepsy and moderate-to-severe developmental impairment. (tian2023phenotypicexpansionof pages 1-2, tian2023phenotypicexpansionof pages 9-10, tian2023phenotypicexpansionof pages 3-5, tian2023phenotypicexpansionof pages 5-8, tian2023phenotypicexpansionof media 96944f0f)

Table: This table condenses the current evidence base for KCNH1-associated disorder across clinical, genetic, mechanistic, diagnostic, and management domains. It is useful for rapid knowledge-base population because it highlights established findings, numeric evidence, ontology suggestions, and major evidence gaps.

Evidence framework

Evidence is primarily aggregated disease-level evidence from published case reports, small cohorts, functional studies, and reviews—not population registries or longitudinal EHR studies. Patient-level observations are frequently re-aggregated across papers, so denominators vary by feature and should not be interpreted as unbiased prevalence estimates. The most informative recent sources are Tian et al. (published online October 2022; journal issue 2023; DOI 10.1111/cns.14001), Napoli et al. (31 May 2022; DOI 10.1007/s12035-022-02886-4), and the 2024 dental case report by Gu et al. (July 2024; DOI 10.22514/jocpd.2024.095). Foundational KCNH1 disease-association literature is indexed under PMID 25420144 and 25915598. (OpenTargets Search: Temple-Baraitser syndrome,Zimmermann-Laband syndrome-KCNH1, tian2023phenotypicexpansionof pages 1-2, napoli2022potassiumchannelkcnh1 pages 1-2, gu2024clinicalandgenetic pages 1-2)

1. Disease information

Definition and scope

The disorder is a Mendelian, dominant, syndromic neurodevelopmental channelopathy. Its defining manifestations are variable combinations of developmental delay/intellectual disability, early hypotonia, epilepsy, characteristic craniofacial appearance, gingival enlargement, hypoplasia of terminal phalanges and nails, and occasionally hypertrichosis. Mild presentations may consist of febrile seizures or epilepsy without dysmorphism or intellectual disability. (gripp2021syndromicdisorderscaused pages 1-2, gripp2021syndromicdisorderscaused pages 9-10, tian2023phenotypicexpansionof pages 3-5)

Identifiers and synonyms

• Gene: KCNH1; approved name potassium voltage-gated channel subfamily H member 1; Ensembl ENSG00000143473.
• Protein synonyms: Kv10.1, Eag1, ether-à-go-go 1.
• Temple–Baraitser syndrome: OMIM #611816; Open Targets/EFO EFO:0009062.
• Zimmermann–Laband syndrome 1: OMIM #135500; broader Zimmermann–Laband syndrome has MONDO:0000200.
• Other names: KCNH1-related neurodevelopmental disorder, KCNH1-related developmental and epileptic encephalopathy, KCNH1-associated epilepsy, and syndromic neurodevelopmental K+ channelopathy. (OpenTargets Search: Temple-Baraitser syndrome,Zimmermann-Laband syndrome-KCNH1, napoli2022potassiumchannelkcnh1 pages 9-11, napoli2022potassiumchannelkcnh1 pages 1-2)
• No specific ICD-10, ICD-11, or MeSH code unique to the complete KCNH1 spectrum was established in the retrieved sources; coding generally uses broader congenital-malformation, intellectual-disability, or epilepsy categories.

Important nomenclature distinction: KCNH1 causes ZLS1. ATP6V1B2-related disease is commonly called ZLS2, while KCNN3-related disease is ZLS3; KCNK4 causes an overlapping FHEIG/channelopathy phenotype. These should not be merged into a KCNH1 gene-specific entry. (gripp2021syndromicdisorderscaused pages 1-2, gripp2021syndromicdisorderscaused pages 9-10)

2. Etiology

Causal factor

The primary cause is a pathogenic or likely pathogenic germline heterozygous KCNH1 variant, most often de novo and missense. Activating variants alter Kv10.1 gating and increase potassium conductance over physiologically important negative membrane potentials. The relationship between increased K+ conductance and epilepsy is not simply “more potassium current equals less excitation”: cell-type-specific effects, impaired inhibitory-network function, developmental signaling, and altered ciliary biology may all contribute. (tian2023phenotypicexpansionof pages 9-10, tian2023phenotypicexpansionof pages 5-8, napoli2022potassiumchannelkcnh1 pages 9-11)

Genetic risk factors

• Recurrent severe-disease residues include Arg357, Leu489, Ala492, Ile/Leu494, and Gly496, concentrated in S4 or S6/channel-gating regions.
• Reported variants include p.Ile113Thr, p.Lys199Arg, p.Arg330Gln under the short isoform/p.Arg357Gln under the long isoform, p.Arg357Trp, p.Leu489Phe, p.Ala492Thr, p.Gly496Glu, p.Arg535*, p.Val713Glu, and the 2024 p.Pro733Leu case.
• Variants p.Ile113Thr and p.Arg357Trp were absent from gnomAD in Tian et al.; severe recurrent missense variants are generally exceptionally rare or absent from population databases. (tian2023phenotypicexpansionof pages 2-3, wrede2021novelkcnh1mutations pages 6-8, tian2023phenotypicexpansionof pages 3-5, gu2024clinicalandgenetic pages 6-7)
• Somatic mosaicism: p.Val713Glu was detected in resected focal cortical dysplasia type IIb tissue but not adjacent healthy brain or blood, supporting a brain-somatic mechanism for focal epilepsy. (wrede2021novelkcnh1mutations pages 6-8)

Environmental, lifestyle, and infectious factors

No toxin, infection, diet, smoking, occupational exposure, or other environmental factor is known to cause the disorder. Fever, hot-water bathing, and acute illness may trigger seizures or status epilepticus in susceptible individuals but are not etiologic. One p.Arg357Trp patient had seizures precipitated by low-grade fever or hot-water bathing. (tian2023phenotypicexpansionof pages 3-5)

Protective factors and gene–environment interaction

No validated genetic or environmental protective factor has been identified. Prompt fever management and an individualized seizure-rescue plan may reduce complications, but this is tertiary risk management rather than primary prevention. Modifier genes are unconfirmed; apparent severity differences remain only partly explained by variant location, functional strength, and mosaic fraction. (tian2023phenotypicexpansionof pages 5-8)

3. Phenotypes

Quantified syndromic phenotype

In 27 individuals with dominant KCNH1 variants summarized by Gripp et al.:

• Great-toe nail absence/hypoplasia: 24/27 (89%).
• Other fingernail/toenail absence or hypoplasia: 16/20 (80%).
• Gingival enlargement: 15/19 (79%).
• Hypertrichosis: 3/16 (19%).
• Terminal phalangeal hypoplasia: approximately 76%.
• Proximally placed/long thumb: 78%.
• Long great toes: 63%.
• Broad thumb and/or toe: 46%.
• Seizures/epilepsy were reported as a hallmark in approximately 89% of the syndromic KCNH1 group. (gripp2021syndromicdisorderscaused pages 9-10)

Across the broader 51-person KCNH1 spectrum, epilepsy/seizures occurred in 42/51 (82%). (tian2023phenotypicexpansionof pages 3-5, tian2023phenotypicexpansionof pages 5-8)

Phenotype annotations

A 2023 patient with p.Arg357Trp had febrile seizures beginning at eight months, more than ten seizures/hour during fever at 14 months, mild developmental delay, and no nail or facial abnormalities. Conversely, severe classic patients may have profound ID, absent ambulation, gingival hyperplasia requiring repeated operations, and pharmacoresistant epilepsy. (tian2023phenotypicexpansionof pages 3-5, bramswig2015‘splittingversuslumping’ pages 2-4)

Quality of life

No validated EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life dataset was found. Nevertheless, severe epilepsy, inability to walk or communicate, feeding/oral-health burden, repeated gingival surgery, and dependence in activities of daily living imply substantial patient and caregiver burden. The mild end of the spectrum can have normal cognition and seizure remission. (tian2023phenotypicexpansionof pages 3-5, bramswig2015‘splittingversuslumping’ pages 2-4, gu2024clinicalandgenetic pages 1-2)

4. Genetic and molecular information

Gene and protein

KCNH1 is located on chromosome 1 and encodes a 989-amino-acid voltage-gated K+ channel with six transmembrane segments, an N-terminal EAG domain, S1–S4 voltage-sensor region, S5–S6 pore/gate region, C-linker, cyclic nucleotide-binding homology domain (CNBHD), and calmodulin-regulated C terminus. It is highly expressed in brain and also functions in non-excitable cells. (wrede2021novelkcnh1mutations pages 6-8, bramswig2015‘splittingversuslumping’ pages 2-4)

Variant classes and consequences

• Missense variants: dominant disease class; 49/51 (96%) in the largest aggregate analysis.
• Truncating variants: substantially less convincing as a general disease mechanism. p.Arg535* segregated to an affected individual but also an unaffected father and sister; multiple nonsense alleles occur in population controls, indicating that simple haploinsufficiency is comparatively tolerated.
• Germline: usual origin; most severe variants are de novo.
• Mosaic/somatic: documented and generally associated with isolated or focal epilepsy.
• Functional consequence: chiefly gain of function, including negative shifts in voltage-dependent activation and increased whole-cell K+ conductance. Nine missense variants had GOF evidence in summarized electrophysiological studies. (tian2023phenotypicexpansionof pages 9-10, wrede2021novelkcnh1mutations pages 6-8, napoli2022potassiumchannelkcnh1 pages 9-11)

The 2023 distribution is visually summarized in Tian et al.’s channel-domain figure: epilepsy-associated variants are concentrated around gating-critical transmembrane regions, while inherited/non-de novo and non-epilepsy-associated variants are more dispersed. (tian2023phenotypicexpansionof media 96944f0f)

ClinVar/ACMG interpretation

Individual variants should be evaluated under ACMG/AMP criteria using de novo status, population absence, phenotype specificity, recurrence, functional evidence, and domain constraint. A variant outside established hotspots should not be called pathogenic solely because it occurs in KCNH1. Conversely, truncating variants require particular caution because haploinsufficiency is not the established mechanism. The retrieved literature did not provide a complete current ClinVar enumeration or consistent ACMG classification for every reported allele.

Modifier genes, epigenetics, and structural variation

No replicated modifier gene, disease-associated methylation signature, histone alteration, or recurrent pathogenic chromosomal rearrangement specifically defining KCNH1-associated disorder has been established. Large deletions involving KCNH1 may not phenocopy activating missense disease because loss of function is comparatively tolerated. (wrede2021novelkcnh1mutations pages 6-8)

5. Environmental information

There is no evidence that pollution, radiation, toxins, smoking, alcohol, diet, exercise, occupation, or infectious agents cause KCNH1-associated disorder. Fever and hyperthermic exposures can precipitate seizures in some genotypes. This suggests a clinically relevant trigger interaction—constitutive channel dysfunction plus temperature/illness-related reduction in seizure threshold—but not an environmental etiology. No infectious-agent taxonomy or CHEBI toxicant annotation is applicable. (tian2023phenotypicexpansionof pages 3-5)

6. Mechanism and pathophysiology

Upstream causal chain

1. Heterozygous activating KCNH1 missense variant—often in S4/S6 gating regions.
2. Altered Kv10.1 activation/gating, usually activation at more negative potentials and increased K+ conductance.
3. Disturbed membrane-potential and network development. Depending on cell type, increased K+ current may suppress inhibitory interneurons, alter firing adaptation, or disrupt developmental bioelectric signals, producing network disinhibition and epilepsy.
4. Non-conducting/developmental effects: mutant KCNH1 at the ciliary base perturbs ciliogenesis, intraflagellar transport, cell-cycle coordination, and Sonic Hedgehog signaling.
5. Clinical consequences: epilepsy/DEE from abnormal neuronal networks; ID and autism-related behavior from impaired neurodevelopment; nail, terminal-phalanx, craniofacial, and gingival abnormalities from altered morphogenesis. (tian2023phenotypicexpansionof pages 5-8, napoli2022potassiumchannelkcnh1 pages 9-11, napoli2022potassiumchannelkcnh1 pages 1-2)

Ciliary and signaling mechanism

Napoli et al. localized KCNH1 to pre-ciliary vesicles and the ciliary pocket in human dermal fibroblasts and hTERT-RPE1 cells. Pathogenic p.Leu352Val and p.Arg330Gln variants caused short or fragmented cilia, bulbous tips, multiciliation, defective IFT172 accumulation, impaired assembly/disassembly, ciliary-tip excision, and ectopic SHH activation. The authors’ abstract states that the variants “perturb cilia morphology, assembly/disassembly, and Sonic Hedgehog signaling.” This is in-vitro human-cell evidence, not proof that every patient manifestation is a classical ciliopathy. (napoli2022potassiumchannelkcnh1 pages 9-11, napoli2022potassiumchannelkcnh1 pages 1-2)

Suggested ontology annotations

• GO biological process: potassium ion transmembrane transport; regulation of membrane potential; action-potential repolarization; cilium assembly; cilium organization; regulation of cell cycle; intraciliary transport; Hedgehog signaling.
• GO molecular function: voltage-gated potassium channel activity.
• GO cellular component: plasma membrane; voltage-gated potassium channel complex; primary cilium; ciliary pocket; pre-ciliary vesicle.
• Cell Ontology: neuron; GABAergic neuron (mechanistically plausible but not directly proven for KCNH1); dermal fibroblast; retinal pigment epithelial cell; neural progenitor cell.

No reproducible patient transcriptomic, proteomic, metabolomic, lipidomic, single-cell, spatial-transcriptomic, or integrated multi-omic signature was found. Computational structural modeling predicts variant-specific destabilization or conformational change but remains supporting rather than definitive functional evidence. (wrede2021novelkcnh1mutations pages 6-8, tian2023phenotypicexpansionof pages 3-5)

7. Anatomical structures affected

• Primary organ/system: central nervous system—developing cerebral cortex and neuronal networks (UBERON:0000955 brain; UBERON:0001950 neocortex).
• Oral/craniofacial: gingiva, dentition, maxillofacial structures (UBERON:0001828 gingiva; UBERON:0001091 tooth).
• Musculoskeletal/integumentary: terminal phalanges, thumbs, great toes, and nail units.
• Subcellular: neuronal plasma membrane, primary cilium/ciliary pocket, pre-ciliary vesicles, and channel complex.
• Secondary involvement: scoliosis, joint hypermobility, strabismus, and corpus-callosum anomalies occur in subsets.

Digital and nail involvement is usually bilateral, although detailed lateralization is inconsistently reported. Focal cortical dysplasia, when driven by a brain-somatic variant, is anatomically localized rather than generalized. (gripp2021syndromicdisorderscaused pages 5-6, wrede2021novelkcnh1mutations pages 6-8, napoli2022potassiumchannelkcnh1 pages 9-11)

8. Temporal development

• Onset: congenital malformations and hypotonia may be evident neonatally; developmental delay emerges during infancy. Seizures range from neonatal onset to adolescence but most severe hotspot-associated epilepsy begins before age two.
• In 14 patients with variants at p.Leu489, p.Ala492, or p.Gly496, all had epilepsy onset before two years; five p.Ile494Val patients had later onset averaging about five years. (tian2023phenotypicexpansionof pages 5-8)
• Course: chronic and lifelong for developmental/dysmorphic manifestations. Epilepsy may remit, remain medication-responsive, or become recurrent/drug-resistant. A mother carrying p.Ile113Thr had four to five febrile seizures from 1.5 to five years and normal adult neuropsychological status. (tian2023phenotypicexpansionof pages 3-5)
• Critical period: prenatal/early postnatal neurodevelopment is probably a major vulnerability window; prevention of prolonged seizures and status epilepticus is a practical postnatal intervention window.
• No formal stages or remission criteria exist. Facial appearance, nail abnormalities, and gingival enlargement may become more apparent with age. (bramswig2015‘splittingversuslumping’ pages 2-4)

9. Inheritance and population

Inheritance

• Pattern: autosomal dominant.
• Origin: predominantly de novo in severe syndromic disease—38/51 in the 2023 aggregate dataset.
• Penetrance: probably high for recurrent activating hotspot variants, but not formally quantified. It can be low for some truncating alleles; p.Arg535* was present in an unaffected father and sister.
• Expressivity: markedly variable, ranging from normal cognition with self-limited febrile seizures to profound DEE and multiple congenital abnormalities.
• Mosaicism: somatic and mosaic variants are documented. Parental germline mosaicism remains a biologically plausible recurrence mechanism even when parental blood testing is negative.
• No anticipation, founder effect, consanguinity association, or population-specific carrier frequency is established. (tian2023phenotypicexpansionof pages 1-2, wrede2021novelkcnh1mutations pages 6-8, tian2023phenotypicexpansionof pages 3-5)

Epidemiology

Population prevalence and incidence are unknown. The largest literature aggregation available here comprised only 51 individuals. In one trio-WES-based intellectual-disability series, de novo pathogenic KCNH1 variants occurred in 4/1,447 (0.3%), but this is a diagnostic yield in an enriched ID cohort—not population prevalence. No robust sex ratio, ethnic enrichment, or geographic concentration is apparent. (tian2023phenotypicexpansionof pages 3-5, bramswig2015‘splittingversuslumping’ pages 2-4)

10. Diagnostics

Clinical evaluation

Consider KCNH1 testing in a child with developmental delay/ID plus epilepsy, particularly when accompanied by broad or long thumbs/great toes, nail hypoplasia, gingival enlargement, coarse facial features, or neonatal hypotonia. The absence of dysmorphism does not exclude KCNH1-related isolated epilepsy. (tian2023phenotypicexpansionof pages 3-5, tian2023phenotypicexpansionof pages 5-8)

Recommended characterization includes:

1. Detailed developmental, neurologic, dysmorphology, nail/digital, dental, and three-generation family assessment.
2. EEG; prolonged/video EEG when events or subclinical seizures are suspected.
3. Brain MRI for malformations, focal cortical dysplasia, corpus-callosum abnormalities, or status-related injury.
4. Dental/periodontal assessment, swallowing/nutrition review, ophthalmologic examination, and orthopedic assessment when indicated.
5. Standard safety laboratory monitoring dictated by antiseizure treatment; no disease-specific blood, urine, enzyme, metabolic, or circulating biomarker exists. (gripp2021syndromicdisorderscaused pages 5-6, tian2023phenotypicexpansionof pages 3-5, gu2024clinicalandgenetic pages 1-2)

Genetic-testing strategy

• Preferred: trio exome sequencing or trio genome sequencing, or a comprehensive epilepsy/neurodevelopmental panel that includes KCNH1.
• Confirmation: Sanger confirmation and parental testing to establish de novo status.
• Mosaicism: high-depth sequencing of affected tissue should be considered when focal cortical dysplasia is resected and blood testing is negative or inconclusive.
• WGS: useful for poorly covered exons, mosaicism, structural/noncoding variants, or negative exome/panel results.
• CMA: appropriate when multiple congenital anomalies or ID warrant copy-number analysis, but it is not the optimal test for the usual activating single-nucleotide variants.
• Karyotype, FISH, mitochondrial sequencing, and repeat-expansion assays are not disease-specific tests.
• RNA-seq, proteomics, metabolomics, liquid biopsy, or methylation profiling are not validated diagnostic modalities. (tian2023phenotypicexpansionof pages 2-3, wrede2021novelkcnh1mutations pages 6-8, bramswig2015‘splittingversuslumping’ pages 2-4)

Differential diagnosis

Major differentials include ATP6V1B2-related ZLS2/DDOD, KCNN3-related ZLS3, KCNK4-related FHEIG syndrome, Coffin–Siris syndromes, DOORS syndrome, Cantú syndrome, Cornelia de Lange spectrum, and other genetic DEEs. Nail/phalangeal pattern, gingival enlargement, hearing loss, hypertrichosis, cardiac findings, and molecular testing are discriminating features. (gripp2021syndromicdisorderscaused pages 1-2, gripp2021syndromicdisorderscaused pages 9-10)

No consensus clinical diagnostic criteria or newborn-screening assay exists.

11. Outcome and prognosis

Prognosis is genotype- and phenotype-dependent. Inherited or low-level mosaic variants tend to be associated with later seizure onset, less ID/DD, and a higher probability of seizure freedom. De novo S4/S6 hotspot variants more often produce early DEE, severe disability, and recurrent or drug-resistant seizures. (tian2023phenotypicexpansionof pages 1-2, tian2023phenotypicexpansionof pages 5-8)

• ASM response: 20/34 patients with documented epilepsy treatment (59%) responded well.
• Status epilepticus: approximately 21% of reported epilepsy patients experienced SE; super-refractory SE occurred in two newly reported patients.
• Mortality: one patient died 20 days after seizure onset following uncontrollable seizures, acute encephalopathy, and severe brain damage. This demonstrates possible early mortality but does not establish a mortality rate.
• No five- or ten-year survival estimates, life-expectancy model, formal SUDEP rate, or prognostic biomarker has been published in the retrieved evidence. (tian2023phenotypicexpansionof pages 3-5, tian2023phenotypicexpansionof pages 9-10)

Long-term morbidity may include profound cognitive and communication impairment, non-ambulation, recurrent seizures, dental/periodontal disease, and dependence for daily care. Recovery from the underlying developmental disorder is not expected, although seizure control, rehabilitation, and oral surgery can improve function.

12. Treatment

Antiseizure treatment

There is no approved disease-modifying or KCNH1-selective therapy. Treatment follows seizure type and standard pediatric epilepsy/DEE practice. Reported agents include valproate, levetiracetam, lamotrigine, carbamazepine, oxcarbazepine, phenytoin, phenobarbital, clobazam, sulthiame, lacosamide, diazepam, and intravenous midazolam; cannabidiol was effective in at least one published case. Responses are heterogeneous, and several patients were resistant to multiple drugs. (wrede2021novelkcnh1mutations pages 2-4, tian2023phenotypicexpansionof pages 8-9, tian2023phenotypicexpansionof pages 9-10)

A p.Arg357Trp child with fever-triggered frequent seizures failed diazepam, valproate, and phenobarbital acutely, responded to continuous IV midazolam, and subsequently remained seizure-free on valproate 22 mg/kg/day through age two. This is anecdotal evidence, not a genotype-specific algorithm. (tian2023phenotypicexpansionof pages 3-5)

Suggested NCIT annotations: Anticonvulsant Therapy, Valproic Acid, Levetiracetam, Clobazam, Midazolam, and Cannabidiol.

Oral and dental treatment

For mild gingival enlargement, meticulous periodontal hygiene and surveillance are appropriate. Severe enlargement impairing eruption, mastication, speech, lip closure, or hygiene can require gingivectomy/gingivoplasty. In the 2024 p.Pro733Leu case, surgery restored mastication and gingival form; slight recurrence was present at two years, while permanent-tooth eruption progressed. Stainless-steel crowns successfully treated carious primary molars without secondary caries or periapical disease at follow-up. (gu2024clinicalandgenetic pages 1-2, gu2024clinicalandgenetic pages 6-7)

Suggested NCIT terms: Gingivectomy, Gingivoplasty, Dental Restoration Procedure.

Supportive treatment

Early physical, occupational, speech/language, feeding, behavioral, and augmentative-communication therapies are appropriate. Orthotics, mobility equipment, scoliosis surveillance, nutrition support, and caregiver respite should be individualized. A written fever and seizure-rescue plan is important for patients with temperature-sensitive epilepsy.

Experimental and precision therapies

No relevant KCNH1-specific interventional ClinicalTrials.gov study, gene therapy, ASO/siRNA program, CRISPR trial, cell therapy, or validated channel-blocker trial was found. Kv10.1 blockade is mechanistically attractive for activating variants, but currently available blockers have substantial off-target/cardiac or oncologic-development concerns; clinical use cannot be recommended without disease-specific safety and efficacy studies.

13. Prevention

• Primary prevention: no lifestyle, vaccine, environmental intervention, or medication prevents a de novo KCNH1 variant.
• Reproductive prevention/options: genetic counseling; parental testing; prenatal diagnosis or preimplantation genetic testing when the familial pathogenic variant is known.
• Recurrence counseling: for an apparently de novo variant, recurrence is low but not zero because parental germline mosaicism cannot be excluded. An affected heterozygous individual has up to a 50% transmission risk, modified by penetrance and expressivity.
• Secondary prevention: no population or newborn screening program. Cascade testing is appropriate in families with an inherited variant, interpreted cautiously for truncating/VUS alleles.
• Tertiary prevention: seizure-rescue planning, rapid management of prolonged seizures/fever, medication adherence, developmental intervention, aspiration/nutrition assessment, dental hygiene, periodontal surveillance, and regular assessment for orthopedic and visual complications. (wrede2021novelkcnh1mutations pages 6-8, tian2023phenotypicexpansionof pages 3-5, gu2024clinicalandgenetic pages 1-2)

Immunization should follow routine schedules; no KCNH1-specific vaccine indication or contraindication was identified.

14. Other species and natural disease

KCNH1/Eag-family channels are evolutionarily conserved, including homology to the Drosophila melanogaster ether-à-go-go channel. Xenopus oocytes are extensively used for functional expression and electrophysiology. (tian2023phenotypicexpansionof pages 9-10, bramswig2015‘splittingversuslumping’ pages 2-4)

No naturally occurring companion-animal, livestock, or wildlife syndrome convincingly equivalent to human KCNH1-associated disorder was identified. Therefore, no breed/VBO association, veterinary prevalence, cross-species transmission, or zoonotic potential applies. This is a genetic channelopathy and is not transmissible between species.

15. Model organisms and experimental models

Available systems

• Xenopus laevis oocytes: heterologous channel electrophysiology; several missense variants demonstrate GOF gating.
• HEK293T and CHO cells: patch-clamp and channel-expression assays.
• Human dermal fibroblasts: patient/mutant-cell analysis of ciliary morphology, assembly/disassembly, cell cycle, and SHH signaling.
• hTERT-RPE1 cells: localization to pre-ciliary vesicles/ciliary pocket and mechanistic ciliogenesis experiments.
• Computational models: AlphaFold/Robetta structures and stability/hydrogen-bond predictions for variant interpretation. (tian2023phenotypicexpansionof pages 9-10, wrede2021novelkcnh1mutations pages 6-8, tian2023phenotypicexpansionof pages 3-5, napoli2022potassiumchannelkcnh1 pages 9-11)

Strengths and limitations

These models directly test channel gating and cellular consequences but do not reproduce organism-level cognition, epilepsy networks, craniofacial development, or longitudinal treatment response. No dedicated KCNH1 knock-in mouse, zebrafish, Drosophila syndrome model, patient-derived neuronal iPSC model, or brain organoid with validated recapitulation of the human disorder was retrieved. Such models are a major research need for resolving the potassium-channel GOF epilepsy paradox and testing Kv10.1-selective therapies.

Direct abstract quotations supporting central conclusions

• Tian et al. defined the objective succinctly: “This study aimed to expand the phenotypic spectrum of KCNH1 and explore the correlations between epilepsy and molecular sub-regional locations.” Their 2023 analysis supports inclusion of isolated epilepsy within the spectrum. (tian2023phenotypicexpansionof pages 1-2)
• Gripp et al. described the shared phenotype as including “developmental delay and/or ID, coarse facial features, gingival enlargement, distal digital hypoplasia, and hypertrichosis” and proposed a subgroup of syndromic neurodevelopmental K+ channelopathies. (gripp2021syndromicdisorderscaused pages 1-2)
• Napoli et al. reported that KCNH1 variants “perturb cilia morphology, assembly/disassembly, and Sonic Hedgehog signaling,” supplying a developmental mechanism beyond altered electrical excitability. (napoli2022potassiumchannelkcnh1 pages 1-2)
• Von Wrede et al. concluded that their cases ranged “from developmental and epileptic encephalopathy with intellectual disability (DEE) to genetic generalized epilepsy (GGE)” and that GOF rather than haploinsufficiency is central to pathogenicity. (wrede2021novelkcnh1mutations pages 1-2)

Knowledge gaps and expert assessment

The evidence strongly supports KCNH1 gain of function as the principal upstream mechanism, but current clinical knowledge remains limited by small, overlapping case series, inconsistent phenotype ascertainment, and lack of prospective natural-history data. The most defensible knowledge-base representation is therefore a KCNH1-associated disorder spectrum, with TMBTS, ZLS1, DEE, and isolated epilepsy retained as phenotype labels rather than rigidly separate molecular diseases. High priorities are an international longitudinal registry, standardized seizure/developmental and quality-of-life outcomes, functional classification of individual variants, deep sequencing for mosaicism, patient-derived neuronal models, and development of safe Kv10.1-selective modulation. (tian2023phenotypicexpansionof pages 1-2, gripp2021syndromicdisorderscaused pages 1-2, tian2023phenotypicexpansionof pages 5-8, napoli2022potassiumchannelkcnh1 pages 9-11)

References

1. (tian2023phenotypicexpansionof pages 1-2): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

2. (wrede2021novelkcnh1mutations pages 1-2): Randi von Wrede, Monika Jeub, Idil Ariöz, Christian E. Elger, Hubertus von Voss, Hanns-Georg Klein, Albert J. Becker, Susanne Schoch, Rainer Surges, and Wolfram S. Kunz. Novel kcnh1 mutations associated with epilepsy: broadening the phenotypic spectrum of kcnh1-associated diseases. Genes, 12:132, Jan 2021. URL: https://doi.org/10.3390/genes12020132, doi:10.3390/genes12020132. This article has 20 citations.

3. (gripp2021syndromicdisorderscaused pages 1-2): Karen W. Gripp, Sarah F. Smithson, Ingrid J. Scurr, Julia Baptista, Anirban Majumdar, Germaine Pierre, Maggie Williams, Lindsay B. Henderson, Ingrid M. Wentzensen, Heather McLaughlin, Lisette Leeuwen, Marleen E. H. Simon, Ellen van Binsbergen, Mary Beth P. Dinulos, Julie D. Kaplan, Anne McRae, Andrea Superti-Furga, Jean-Marc Good, and Kerstin Kutsche. Syndromic disorders caused by gain-of-function variants in kcnh1, kcnk4, and kcnn3—a subgroup of k+ channelopathies. European Journal of Human Genetics, 29:1384-1395, Feb 2021. URL: https://doi.org/10.1038/s41431-021-00818-9, doi:10.1038/s41431-021-00818-9. This article has 51 citations and is from a domain leading peer-reviewed journal.

4. (tian2023phenotypicexpansionof pages 9-10): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

5. (tian2023phenotypicexpansionof pages 3-5): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

6. (tian2023phenotypicexpansionof pages 5-8): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

7. (tian2023phenotypicexpansionof media 96944f0f): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

8. (napoli2022potassiumchannelkcnh1 pages 1-2): Giulia Napoli, Noemi Panzironi, Alice Traversa, Caterina Catalanotto, Valentina Pace, Francesco Petrizzelli, Agnese Giovannetti, Sara Lazzari, Carlo Cogoni, Marco Tartaglia, Massimo Carella, Tommaso Mazza, Antonio Pizzuti, Chiara Parisi, and Viviana Caputo. Potassium channel kcnh1 activating variants cause altered functional and morphological ciliogenesis. Molecular Neurobiology, 59:4825-4838, May 2022. URL: https://doi.org/10.1007/s12035-022-02886-4, doi:10.1007/s12035-022-02886-4. This article has 15 citations and is from a peer-reviewed journal.

9. (gu2024clinicalandgenetic pages 1-2): Yang Gu, Xiaoxue Yang, Xiaohe Guo, Meiling Wu, Xiaoyao Huang, Hao Guo, Shijie Li, Fei Fu, Mingyuan Liu, K. Xuan, and Anqi Liu. Clinical and genetic evaluations of zimmermann-laband syndrome with gingival fibromatosis: a rare case report. The Journal of clinical pediatric dentistry, 48 4:206-213, Jul 2024. URL: https://doi.org/10.22514/jocpd.2024.095, doi:10.22514/jocpd.2024.095. This article has 3 citations.

10. (OpenTargets Search: Temple-Baraitser syndrome,Zimmermann-Laband syndrome-KCNH1): Open Targets Query (Temple-Baraitser syndrome,Zimmermann-Laband syndrome-KCNH1, 2 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

11. (wrede2021novelkcnh1mutations pages 6-8): Randi von Wrede, Monika Jeub, Idil Ariöz, Christian E. Elger, Hubertus von Voss, Hanns-Georg Klein, Albert J. Becker, Susanne Schoch, Rainer Surges, and Wolfram S. Kunz. Novel kcnh1 mutations associated with epilepsy: broadening the phenotypic spectrum of kcnh1-associated diseases. Genes, 12:132, Jan 2021. URL: https://doi.org/10.3390/genes12020132, doi:10.3390/genes12020132. This article has 20 citations.

12. (bramswig2015‘splittingversuslumping’ pages 2-4): Nuria C. Bramswig, C. W. Ockeloen, J. C. Czeschik, A. J. van Essen, R. Pfundt, J. Smeitink, B. T. Poll-The, H. Engels, T. M. Strom, D. Wieczorek, T. Kleefstra, and H.-J. Lüdecke. ‘splitting versus lumping’: temple–baraitser and zimmermann–laband syndromes. Human Genetics, 134:1089-1097, Aug 2015. URL: https://doi.org/10.1007/s00439-015-1590-1, doi:10.1007/s00439-015-1590-1. This article has 43 citations and is from a peer-reviewed journal.

13. (gripp2021syndromicdisorderscaused pages 9-10): Karen W. Gripp, Sarah F. Smithson, Ingrid J. Scurr, Julia Baptista, Anirban Majumdar, Germaine Pierre, Maggie Williams, Lindsay B. Henderson, Ingrid M. Wentzensen, Heather McLaughlin, Lisette Leeuwen, Marleen E. H. Simon, Ellen van Binsbergen, Mary Beth P. Dinulos, Julie D. Kaplan, Anne McRae, Andrea Superti-Furga, Jean-Marc Good, and Kerstin Kutsche. Syndromic disorders caused by gain-of-function variants in kcnh1, kcnk4, and kcnn3—a subgroup of k+ channelopathies. European Journal of Human Genetics, 29:1384-1395, Feb 2021. URL: https://doi.org/10.1038/s41431-021-00818-9, doi:10.1038/s41431-021-00818-9. This article has 51 citations and is from a domain leading peer-reviewed journal.

14. (napoli2022potassiumchannelkcnh1 pages 9-11): Giulia Napoli, Noemi Panzironi, Alice Traversa, Caterina Catalanotto, Valentina Pace, Francesco Petrizzelli, Agnese Giovannetti, Sara Lazzari, Carlo Cogoni, Marco Tartaglia, Massimo Carella, Tommaso Mazza, Antonio Pizzuti, Chiara Parisi, and Viviana Caputo. Potassium channel kcnh1 activating variants cause altered functional and morphological ciliogenesis. Molecular Neurobiology, 59:4825-4838, May 2022. URL: https://doi.org/10.1007/s12035-022-02886-4, doi:10.1007/s12035-022-02886-4. This article has 15 citations and is from a peer-reviewed journal.

15. (gu2024clinicalandgenetic pages 6-7): Yang Gu, Xiaoxue Yang, Xiaohe Guo, Meiling Wu, Xiaoyao Huang, Hao Guo, Shijie Li, Fei Fu, Mingyuan Liu, K. Xuan, and Anqi Liu. Clinical and genetic evaluations of zimmermann-laband syndrome with gingival fibromatosis: a rare case report. The Journal of clinical pediatric dentistry, 48 4:206-213, Jul 2024. URL: https://doi.org/10.22514/jocpd.2024.095, doi:10.22514/jocpd.2024.095. This article has 3 citations.

16. (tian2023phenotypicexpansionof pages 2-3): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

17. (tian2023phenotypicexpansionof pages 8-9): Mao‐Qiang Tian, Ren‐Ke Li, Fan Yang, Xiao‐Mei Shu, Juan Li, Jing Chen, Long‐Ying Peng, Xiao‐Hua Yu, and Chang‐Jian Yang. Phenotypic expansion of kcnh1 ‐associated disorders to include isolated epilepsy and its associations with genotypes and molecular sub‐regional locations. CNS Neuroscience & Therapeutics, 29:270-281, Oct 2023. URL: https://doi.org/10.1111/cns.14001, doi:10.1111/cns.14001. This article has 15 citations and is from a peer-reviewed journal.

18. (wrede2021novelkcnh1mutations pages 2-4): Randi von Wrede, Monika Jeub, Idil Ariöz, Christian E. Elger, Hubertus von Voss, Hanns-Georg Klein, Albert J. Becker, Susanne Schoch, Rainer Surges, and Wolfram S. Kunz. Novel kcnh1 mutations associated with epilepsy: broadening the phenotypic spectrum of kcnh1-associated diseases. Genes, 12:132, Jan 2021. URL: https://doi.org/10.3390/genes12020132, doi:10.3390/genes12020132. This article has 20 citations.

19. (gripp2021syndromicdisorderscaused pages 5-6): Karen W. Gripp, Sarah F. Smithson, Ingrid J. Scurr, Julia Baptista, Anirban Majumdar, Germaine Pierre, Maggie Williams, Lindsay B. Henderson, Ingrid M. Wentzensen, Heather McLaughlin, Lisette Leeuwen, Marleen E. H. Simon, Ellen van Binsbergen, Mary Beth P. Dinulos, Julie D. Kaplan, Anne McRae, Andrea Superti-Furga, Jean-Marc Good, and Kerstin Kutsche. Syndromic disorders caused by gain-of-function variants in kcnh1, kcnk4, and kcnn3—a subgroup of k+ channelopathies. European Journal of Human Genetics, 29:1384-1395, Feb 2021. URL: https://doi.org/10.1038/s41431-021-00818-9, doi:10.1038/s41431-021-00818-9. This article has 51 citations and is from a domain leading peer-reviewed journal.

Artifacts

• Edison artifact artifact-00